NSAID ulcers: prevalence and prevention

References

• Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985;28:686–92.
   PubMed Web of Science ®Google Scholar
• Anti-arthritic medication usage: United States, 1991. Stat Bull Metrop Insur Co. 1992;73:25–34.
   PubMedGoogle Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340: 1888–99.
   PubMed Web of Science ®Google Scholar
• Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Ftheumatol Suppl 1991;28:6–10.
   PubMedGoogle Scholar
• Fries JF. Assessing and understanding patient risk. Scand J Ftheumatol Suppl 1992;92:21–4.
   PubMedGoogle Scholar
• Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A ran-domized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241–9.
   PubMed Web of Science ®Google Scholar
• Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998;104:235-29S.
   Google Scholar
• Agrawal N. Risk factors for gastrointestinal ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs) [published erratum appears in J Fam Pract 1991 Jul;33(1):161. J Fam Pract 1991;32:619–24.
   PubMed Web of Science ®Google Scholar
• Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91:213–22.
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115:787–96.
   Google Scholar
• Shorr RI, Ray WA, Daugherty JR, et al. Concurrent use of nons-teroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665–70.
   PubMedGoogle Scholar
• Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleed-ing and perforation associated with individual non-steroidal anti-inflammatory drugs [published erratum appears in Lancet 1994 Apr 23;343(8904):1048]. Lancet 1994;343:769–72.
   PubMed Web of Science ®Google Scholar
• Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257–63.
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Walker AM, Perez Gutthann S. Nonsteroi-dal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology 1992;3:337–42.
   Google Scholar
• Lanza LL, Walker AM, Bortnichak EA, et al. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study. Arch Intern Med 1995;155:1371–7.
   PubMedGoogle Scholar
• Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563–6.
   PubMed Web of Science ®Google Scholar
• Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med 1986;104:390–8.
   PubMed Web of Science ®Google Scholar
• Hochain P, Berkelmans I, Czernichow P, et al. Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case-control study. Eur J Gastroenterol Hepatol 1995;7:419–26.
   PubMed Web of Science ®Google Scholar
• Simon LS, Goodman T. NSAID-induced gastrointestinal toxicity. Bull Rheum Dis 1995;44:1–5.
   PubMedGoogle Scholar
• Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs [published erratum appears in Lancet 1994 May 21;343(89041302]. Lancet 1994;343:1075–8.
   PubMed Web of Science ®Google Scholar
• Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993;35:219–26.
   Google Scholar
• Smalley WE, Ray WA, Daugherty JR, et al. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995;141:539–45.
   PubMed Web of Science ®Google Scholar
• Graham DY. Prevention of gastroduodenal injury induced by chronic nonsteroidal antiinflammatory drug therapy. Gastro-enterology 1989;96:675–81.
   PubMed Web of Science ®Google Scholar
• Nobunga M, Graham DY, Saito T, et al. NSAID-induced gastrointestinal damage and its management. J Ftheumatol (Ryumachika) 1993;9:279–92.
   Google Scholar
• Graham DY, Smith JL. Effects of aspirin and an aspirin-acetaminophen combination on the gastric mucosa in normal sub-jects. A double-blind endoscopic study. Gastroenterology 1985;88: 1922–5.
   Google Scholar
• Swift GL, Arnold J, Williams GT, et al. A comparison of upper gastrointestinal mucosal damage by standard and delayed-release indomethacin. Aliment Pharmacol Ther 1992;6:717–25.
   PubMed Web of Science ®Google Scholar
• Collins AJ, Davies J, Dixon AS. A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract, in patients with osteoarthritis. Br J Ftheumatol 1988;27:106–109.
   Google Scholar
• Graham DY. Clinical aspects of the protective effects of prostag-landins on non-steroidal anti-inflammatory drug-associated mucosal injury. In: Domschke W, Dannann HG, Peskar BM, et al. editors. Prostaglandins and leukotrienes in gastrointestinal dis-eases. Berlin: Springer-Verlag; 1988. p. 161–7.
   Google Scholar
• Cooper SA. New peripherally acting oral analgesic agents. Annu Rev Pharmacol Toxicol 1983;23:617–47.
   PubMed Web of Science ®Google Scholar
• Brogden RN, Heel RC, Speight TM, et al. Piroxicam: a review of its pharmacological properties and therapeutic efficacy. Drugs 1981;22:165–87.
   PubMed Web of Science ®Google Scholar
• Trewin VF, Lawrence CJ, Rae SA, et al. Development and use of a gastropathy index for ranking the safety of non-steroidal anti-inflammatory drugs in the elderly. J Chin Pharm Ther 1994;19:209–14.
   PubMed Web of Science ®Google Scholar
• Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993;105:1078–88.
   Google Scholar
• LeLorier J. Patterns of prescription of nonsteroidal antiinflam-matory drugs and gastroprotective agents. J Ftheumatol Suppl 1995;43:26–7.
   PubMedGoogle Scholar
• Agrawal NM, Aziz K. Prevention of gastrointestinal complications associated with nonsteroidal antiinflammatory drugs. J Ftheumatol Suppl 1998;51:17–20.
   PubMedGoogle Scholar
• Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol 1996;91: 2080–6.
   PubMed Web of Science ®Google Scholar
• Raskin JB, White RH, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospec-tive, double-blind, multicenter study. Am J Gastroenterol 1996;91: 223–7.
   PubMed Web of Science ®Google Scholar
• Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med 1991;115:195–200.
   PubMed Web of Science ®Google Scholar
• Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract com-plications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156:1530–6.
   PubMed Web of Science ®Google Scholar
• Gunshefski L, Flancbaum L, Brolin RE, et al. Changing patterns in perforated peptic ulcer disease. Am Surg 1990;56:270–4.
   PubMed Web of Science ®Google Scholar
• Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the pre-vention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996;334:1435–9.
   PubMed Web of Science ®Google Scholar
• Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997;112:1817–22.
   PubMed Web of Science ®Google Scholar
• NSAIDs and peptic ulcers [letter]. BMJ 1990;300:814–16.
   Google Scholar
• Graham DY. High-dose famotidine for prevention of NSAID ulcers? Gastroenterology 1997;112:2143–5.
   PubMed Web of Science ®Google Scholar
• Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRO-NAUT) study group. N Engl J Med 1998;338:719–26.
   Google Scholar
• Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole com-pared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus misoprostol for NSAID-induced ulcer management (OMNIUM) study group. N Engl J Med 1998;338:727–34.
   Google Scholar
• Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995;123:344–50.
   PubMed Web of Science ®Google Scholar
• Greenhalgh T. How to read a paper. The basics of evidence-based medicine London: BMJ Publishing Group; 1997.
   Google Scholar
• Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradica-tion of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975–9.
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised con-trolled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter eradication for lesion prevention. Lancet 1998;352: 1016–21.
   Google Scholar
• Gutierrez O, Melo M, Segura AM, et al. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997;32:664–8.
   PubMed Web of Science ®Google Scholar
• El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997;113:15–24.
   PubMed Web of Science ®Google Scholar
• Miehlke S, Hackelsberger A, Meining A, et al. Severe expression of corpus gastritis is characteristic in gastric cancer patients in-fected with Helicobacter pylori. Br J Cancer 1998;78:263–6.
   PubMed Web of Science ®Google Scholar
• Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori aug-ments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996;110:725–32.
   PubMed Web of Science ®Google Scholar
• Sipponen P, Stolte M. Clinical impact of routine biopsies of the gastric antrum and body. Endoscopy 1997;29:671–8.
   PubMed Web of Science ®Google Scholar
• Stolte M, Bethke B. Elimination of Helicobacter pylori under treat-ment with omeprazole. Z Gastroenterol 1990;28:271–4.
   PubMed Web of Science ®Google Scholar
• Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: effi-cacy and safety. Ann Intern Med 1994;121:161–7.
   Google Scholar
• Lamberts R, Creutzfeldt W, Struber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993;104:1356–70.
   PubMed Web of Science ®Google Scholar
• Meining A, Kiel G, Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther 1998;12: 735–40.
   Google Scholar
• Meining A, Bosseckert H, Caspary WF, et al. H2-receptor antago-nists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients. Aliment Pharmacol Ther 1997;11:729–34.
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gas-tritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018–22.
   Google Scholar
• Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal toler-ability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA study group. meloxicam large-scale international study safety assessment. Br J Ftheumatol 1998;37:937–45.
   Google Scholar